Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Next Previous
Trial Profile

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary) ; Cytarabine; Dexamethasone; Imatinib; Methotrexate; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PhALLCON
  • Sponsors Takeda; Takeda Development Center Americas; Takeda Oncology

Most Recent Events

  • 30 Apr 2025 Results(n=238) evaluating Impact of clinical response and treatment tolerability on HRQoL in patients treated with ponatinib or imatinib presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 25 Nov 2024 According to a Takeda media release, Results from two post-hoc analyses from the Phase 3 PhALLCON trial evaluating ICLUSIG versus imatinib plus reduced-intensity chemotherapy will at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.
  • 04 Jun 2024 Results assessing response rates of MRD-neg at any time and PFS by age and BCR::ABL1 variant subgroups presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top